Who are uniQure N.V.'s main suppliers?

uniQure N.V. (QURE) key suppliers include: GENEZEN, Hercules Capital, Inc., Metagenomi Therapeutics, Inc.. View the full supplier network at chainsifter.com/chain/QURE.

Who are uniQure N.V.'s major customers?

uniQure N.V. (QURE) key customers include: CSL-BEHRING, Hercules Capital, Inc., Metagenomi Therapeutics, Inc., NAMSW, COMPANY-INCORPORATED and 5 more. View the full customer network at chainsifter.com/chain/QURE.

What sector is uniQure N.V. in?

uniQure N.V. (QURE) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

uniQure N.V. Suppliers, Customers & Supply Chain (QURE)

3Suppliers

10Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

uniQure N.V. (QURE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships

3Distinct source URLs

5High confidence

0.739Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

uniQure N.V. Suppliers

Ticker	Name	Confidence	Evidence
GENEZEN	GENEZEN	90%	Pursuant to the CSA, Genezen manufactures and supplies CSL Behring’s commercial demand for HEMGENIX® on our behalf.
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from QURE graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from QURE graph: Reciprocal relationship from HTGC g…
MGX	Metagenomi Therapeutics, Inc.	72%	Reciprocal relationship from MGX graph: Reciprocal relationship from QURE graph: Reciprocal relationship from MGX graph: evenue and achieve or maintain profitability; • the level of taxes that we are…

uniQure N.V. Customers

Ticker	Name	Confidence	Evidence
CSL-BEHRING	CSL-BEHRING	90%	We are contractually obligated to supply the Product until such time that these capabilities are transferred to CSL Behring or its designated contract manufacturing organization.
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from QURE graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from QURE graph: Reciprocal relationship from HTGC g…
MGX	Metagenomi Therapeutics, Inc.	72%	Reciprocal relationship from MGX graph: evenue and achieve or maintain profitability; • the level of taxes that we are required to pay; and • the availability of capital. Any reduction in reimburseme…
NAMSW	NAMSW	72%	Reciprocal relationship from NAMSW graph: Reciprocal relationship from QURE graph: Reciprocal relationship from NAMSW graph: form of awards of restricted stock units under the LTIP. Of the total Earn…
COMPANY-INCORPORATED	COMPANY-INCORPORATED	62%	t we own or have licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; ● our competitors might conduct activities in countries where we do not have patent…
CSL-BEHRING-INC	CSL-BEHRING-INC	62%	2.5 million (presented within Other expense in the Consolidated Statement of Operations and Comprehensive Loss) was recorded during the year ended December 31, 2024. 131 Table of Contents The Com…
CSL-BEHRING-LLC	CSL-BEHRING-LLC	62%	6: PSUs Weighted average Number of grant-date fair ordinary shares value Non-vested at December 31, 2025 22,500 $ 15.40 Granted — $ — Vested — …
GENEZEN-HOLDINGS-INC	GENEZEN-HOLDINGS-INC	62%	maining employees terminated effective August 30, 2024. uniQure Inc. and uniQure B.V., both wholly owned subsidiaries of the Company, entered into an APA with Genezen on June 29, 2024. Pursuant to …
GUGGENHEIM-SECURITIES-LLC	GUGGENHEIM-SECURITIES-LLC	62%	t we own or have licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; ● our competitors might conduct activities in countries where we do not have patent…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	62%	t we own or have licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; ● our competitors might conduct activities in countries where we do not have patent…

uniQure N.V. Debt Obligations

Instrument	Description	Confidence	Evidence
QURE-DEBT	Debt stack $61.1M	90%	Market cache reports total debt of $61.1M.
QURE-DEBT-12027	Warrants outstanding: 12	90%	xbrl warrant detail from xbrl 2025-12-31.

uniQure N.V. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for uniQure N.V..

uniQure N.V. Ownership

Holder	Name	Confidence	Evidence
QURE-OWNER-AVORO-CAPITAL-ADVISORS-LLC	Avoro Capital Advisors LLC	90%	13F overlay lists Avoro Capital Advisors LLC as top holder; 222 tracked holders.

uniQure N.V. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
MGX	Metagenomi Therapeutics, Inc.	100.00	1	['customer', 'supplier']
CRSP	CRISPR Therapeutics AG	100.00	2
NTLA	Intellia Therapeutics, Inc.	100.00	2
CRBU	Caribou Biosciences, Inc.	100.00	2
HTGC	Hercules Capital, Inc.	100.00	1	['customer', 'supplier']
EDIT	Editas Medicine, Inc.	100.00	2
SGMO	Sangamo Therapeutics, Inc.	100.00	2
LLY	Eli Lilly and Company	100.00	2
IONS	Ionis Pharmaceuticals, Inc.	100.00	2
NAMSW	NewAmsterdam Pharma Co N.V.	100.00	1	['customer']
DTIL	Precision BioSciences, Inc.	100.00	2
CMPS	COMPASS Pathways plc	50.00	2
ALEC	Alector, Inc.	50.00	2
ENGN	enGene Therapeutics Inc.	50.00	2
MEOBF	MESOBLAST LTD	50.00	2
ALT	Altimmune, Inc.	50.00	2
DYN	Dyne Therapeutics, Inc.	50.00	2
MYGN	Myriad Genetics, Inc.	50.00	2
MDGL	Madrigal Pharmaceuticals, Inc.	50.00	2
KURA	Kura Oncology, Inc.	50.00	2

uniQure N.V. Supply Chain